Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05830396
Other study ID # 202100266
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date May 2023
Est. completion date July 2025

Study information

Verified date May 2023
Source University Medical Center Groningen
Contact Olav Siemeling
Phone 0031 (0)50 3615639
Email o.siemeling@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The most common genetic risk factor for Parkinson's Disease is a heterozygous mutation of the GBA1 gene, encoding the lysosomal enzyme glucocerebrosidase (GCase). Reduced GCase activity is associated with aggregation of the protein alpha synucleine (aSyn) in the central nervous system, which is related to the pathological cause of PD. Ambroxol is a mucolytic expectorant that appears to facilitate the refolding of the misfolded GBA protein thats acts as a chaperone for GCase. This randomized placebo-controlled trial aims to investigate the disease-modifying properties of ambroxol in PD patients with a GBA1-mutation. Patients will undergo motor and cognitive tests, as well as imaging and blood tests.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Parkinson's disease, according to Movement Disorders Society (MDS) criteria (27) - Disease duration of 10 years or less at time of inclusion - PD patients carrying a GBA1 mutation - Able to write written informed consent, understanding study protocol and perform protocol related actions - Willing and able to self-administer oral ambroxol or placebo medication Exclusion Criteria: - The refusal to be informed about an unforeseen clinical finding - Use of an implanted Deep Brain Stimulation (DBS) system - Confirmed dysphagia that would preclude self-administration of ambroxol or placebo tablets - History of known sensitivity to the study medication - Pregnant or breastfeeding women - Participants of childbearing potential that would not use adequate birth control, consisting of a negative pregnancy test at the screening visit and use of accepted contraceptive methods defined as highly effective while participating in the study - MRI incompatible implants in the body - Any clinically significant or unstable medical or surgical condition that in the opinion of the principal investigator may put the participant at risk when participating in the study or may influence the results of the study or affect the participant's ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG), or laboratory tests. Such conditions may include: 1. Impaired renal function (a positive urine dipstick test, and laboratory values below or above: a eGFR <45 ml/min 1,73M2, Sodium 135-145 mmol/L, Potassium 3.5-5.0 mmol/L, Urea 2.5-7.5mmol/L). 2. Moderate/severe hepatic impairment (laboratory values below or above: ASAT 0- 80U/L, ALAT0-90 U/L, GGT > 80 U/L, Alkaline Phosphatase 35-210 U/L).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ambroxol Hydrochloride
Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
Placebo
Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).

Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary MDS-UPDRS3 motor scale Motor scale developed for PD patients, 0-132. 0 means good performance, 132 means very bad performance 60 weeks
Secondary Safety and tolerability measured by incidence of adverse events and possible side effects AE will be monitored and patients will be questioned about side effects every week during the first 3 weeks and after that, every 3 months during the visits all throughout the study. specifically at: 1, 2, 3, 12, 24, 36, 48, 60 weeks
Secondary Glucocerebrosidase (GCase) activity in blood mononuclear cells Measured by the level of sphingolipids in PBMCs 0, 12, 60 weeks
Secondary Striatal F-DOPA uptake as measured by [18] F-DOPA PET scan 0, 60 weeks
Secondary fMRI resting state to investigate the functional architecture and structural MRI for PET-scan Fluctuations in the BOLD signal can be used to investigate the functional architecture and connectivity within the brain. 0, 60 weeks
Secondary Quality of Life (PDQ-39 questionnaire) 0, 60 weeks
Secondary Non Motor Symptoms (NMSS scale) minimum value is 0, maximum value is 360. 0 indicating a good performance, 360 indicating a very bad performance 0, 60 weeks
Secondary Cognition, using the Montreal Cognitive Assessment (MoCA) Range is 0-30, 0 indicating the worst performance, 30 indicating the best performance 0, 60 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A